Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
May 9 DVAX Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call Transcript
May 9 VRNA Verona Pharma gets $650M in financing ahead of June FDA decision on COPD asset
May 9 VRNA Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
May 9 VRNA Verona Pharma GAAP EPS of -$0.04 beats by $0.09
May 9 VRNA Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9 VRNA Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
May 9 APLS Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
May 9 DVAX Dynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...
May 9 DVAX Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
May 8 DVAX Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
May 8 DVAX Dynavax drops 6% as quarterly results miss on both lines
May 8 DVAX Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
May 8 DVAX Dynavax GAAP EPS of -$0.07 misses by $0.04, revenue of $50.79M misses by $4.19M
May 8 DVAX Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8 APLS Apellis stock sell-off over Syfovre sales "overdone," says Citi
May 8 APLS Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
May 8 VRNA Verona Pharma Q1 2024 Earnings Preview
May 8 APLS Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 8 APLS Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
May 7 DVAX Dynavax Q1 2024 Earnings Preview
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags